The pharmaceutical industry is using a novel technique to cheer up people who suffer from clinical depression -- only publishing favorable studies about the effects of its antidepressant medications.
"Fibromyalgia is a real, widespread pain condition," stresses a woman in a television ad for Lyrica, a Pfizer drug that recently became "the first medicine approved to treat the pain condition." But some doctors have their doubts. These skeptics "say vague complaints of chronic pain do not add up to a disease. ... The condition cannot be linked to any environmental or biological causes." Even Dr.
The pharmaceutical industry often uses the need for research and development funds as an excuse for exorbitant drug prices. But a new study by Marc-Andre Gagnon and Dr.
As a paid corporate lobbyist, U.S. presidential candidate Rudy Giuliani helped Purdue Pharma defend its illegal activities to promote the drug Oxycontin, according to New York Times reporters Barry Meier and Eric Lipton. "As a celebrity, Mr.
"Meta-analyses," or reviews of several studies' worth of data on a single drug, influence patient care and healthcare policy. Increasingly, the people carrying out these meta-analyses have financial ties to drug companies. So researchers at Stanford and the University of California, San Francisco set out "to determine whether financial ties to one drug company are associated with favourable results or conclusions in meta-analyses on antihypertensive drugs," which are taken to lower blood pressure.
Ladies and gentlemen, this is the year that the Falsies Awards have truly arrived!
Here at the Center for Media and Democracy (CMD), we've dearly treasured our Falsies since we gave the first awards out in 2004. After 12 months of reporting on the cynical, manipulative and just plain anti-democratic pollution of our information environment, we love adding an extra dash of humor to our work. But this year's Falsies Awards are extra super special.
The United States Senate Committee on Finance has released a damning staff report titled The Intimidation of Dr. John Buse and the Diabetes Drug Avandia.
To mobilize elderly Americans in an effort to overturn the new Medicare coverage policy for erythropoiesis-stimulating agents (ESAs, which boost red blood cell production), Amgen Inc. appears to have borrowed a strategy from the purveyors of alternative medicine.
The company launched a "Protect Cancer Patients" website, where visitors were invited to submit testimonials about the healing powers of ESAs. Also, they could contact members of Congress, or review the Centers for Medicare and Medicaid Services coverage decision and the House and Senate resolutions to vacate it.
On the home page, the site is described as "online headquarters of a national campaign to protect cancer patients on Medicare from a decision denying them ... coverage for needed medicines."
"Amgen's mission is to serve patients, which is why we openly support the Protect Cancer Patients website," Kelley Davenport, an Amgen spokesman, said in an email. "The site educates cancer patients on Medicare and their caregivers about a Medicare policy that impacts cancer patients, so that their voices and concerns are heard by government policymakers.